科美诊断收盘上涨2.01%，滚动市盈率27.63倍，总市值28.52亿元

Group 1 - The core viewpoint of the articles highlights the performance and valuation of Kemei Diagnostics in the medical device industry, indicating a lower PE ratio compared to industry averages [1][2] - Kemei Diagnostics closed at 7.11 yuan, with a PE ratio of 27.63, while the industry average PE is 48.89 [1][2] - The company's total market capitalization is 2.852 billion yuan, ranking 64th in the industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, nine institutions hold shares in Kemei Diagnostics, with a total holding of 206.2876 million shares valued at 1.537 billion yuan [1] - The main business of Kemei Diagnostics includes the research, production, and sales of clinical immunochemistry luminescent diagnostic reagents and instruments [1] - The company has obtained 64 new domestic and international patents during the reporting period, showcasing its innovation capabilities [1] Group 3 - In the latest performance report for the first quarter of 2025, Kemei Diagnostics reported revenue of 81.3001 million yuan, a year-on-year decrease of 27.01%, and a net profit of 14.5428 million yuan, down 62.12% [1] - The gross profit margin for the company stands at 66.88% [1]